TERN-701 CARDINAL study progressing well; dose expansion expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25New ...

The silicon photonics market is estimated to grow at a remarkable Compound Annual Growth Rate (CAGR) of over 26.0% between 2022 and 2032. This indicates that the market is anticip ...

A live webcast of the presentation will be available the day of the event on the “Events” page within the Investors section of Sionna’s website at https://investors.sionnatx.com/. A replay will be ...

STMicroelectronics is unveiling its next generation of proprietary technologies for higher-performing optical interconnect in ...

Optical atomic clocks can increase the precision of time and geographic position a thousandfold in our mobile phones, computers, and GPS systems. However, they are currently too large and complex to ...

A new inhalable gene therapy for cystic fibrosis (CF) has entered Phase I clinical trials, a major milestone on the journey ...

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their mutation type, is being tested in human trials in the UK and Europe.

Boehringer Ingelheim, IP Group, UK Respiratory Gene Therapy Consortium, and OXB launched the first-in-human clinical trial, known as LENTICLAIR 1.

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their mutation type, is being tested in human trials in the UK and Europe.

America’s FDA leadership has been making decisions based on ideology, not drug safety. It's time for a change of priorities.

In diseases like Parkinson's and Alzheimer's, specific proteins misfold and clump together, forming toxic aggregates that ...